Our findings give evidence that individuals with gastric cancer who have the MUC16 wild type were more likely to develop distant metastases and that the clinical outcome of the disease is worse, suggesting that active treatments were essential for these patients in order to achieve a favorable prognosis. This evidence concerns the gene MUC16 and gastric cancer.